Ascendiant Capital Reiterates Buy on Heart Test Laboratories, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has reiterated its Buy rating on Heart Test Laboratories (NASDAQ:HSCS) and maintained a price target of $15.
September 23, 2024 | 5:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital has reiterated its Buy rating on Heart Test Laboratories and maintained a $15 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $15 price target by Ascendiant Capital suggests positive sentiment and confidence in Heart Test Laboratories' future performance. This could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100